Research programme: influenza monoclonal antibodies - Celltrion

Drug Profile

Research programme: influenza monoclonal antibodies - Celltrion

Alternative Names: CT 120; CT-P22; CT-P23; Firivumab

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celltrion
  • Class Monoclonal antibodies
  • Mechanism of Action Influenza virus fusion inhibitors; Influenza virus haemagglutinin glycoprotein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype(Prevention) in South Korea (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in South Korea (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype(Prevention) in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top